LEADERSHIP TEAM

MANAGEMENT TEAM

Our experienced executive team is committed to finding innovative solutions for patients living with infectious diseases, cancer, and monogenic disorders.

Jeffrey A. Galvin<br/>
CEO and Founder

Jeffrey A. Galvin

CEO and
Founder

Jeff earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies.

David Pauza, PhD<br/>
Chief Science Officer

David Pauza, PhD

Chief Science
Officer

David has 35 years of experience in HIV, immunology, virology, and cancer biology, and has held faculty positions and at University of Wisconsin and University of Maryland medical schools. Prior to joining AGT, David was Adjunct Professor of Medicine at the University of Maryland Medical School in Baltimore.

neil-lyons-large

C. Neil Lyons, CPA

Chief Financial Officer & Executive Vice President

Neil has more than 30 years of experience in finance, strategy, raising capital, SEC compliance, and corporate governance in both public and private companies, with over 10 years of that leading finance for publicly-traded, clinical-stage biotechnology companies.

Irene-Tennant-large

Irene Tennant

Director of
Clinical Affairs

Irene brings more than 20 years of experience in clinical research and operations, and has led teams in support of the development of biopharma products and pharmaceutical first in class treatments in gene medicine, oncology, and infectious diseases.

HIV FUNCTIONAL CURE

Our globally recognized HIV functional cure team advises our researchers and participates in the successful administration of pre-clinical and expected clinical activities for AGT103-T HIV therapeutic. Read about our research.

john-rossie-large-1

Dr. John J. Rossi

Chief Science Officer

Dr-Jose-Bordon-large

Dr. Jose Bordon, MD, PhD, AAHIVS

Chief Science Officer

CLINICAL TRIAL PARTNERS

providence-health-foundation-small

Providence Hospital

 

IMMUNO-ONCOLOGY AND LIVER CANCER

Our proprietary lentiviral vectors deliver genetic medicines that have shown to both disable key drivers of tumor growth or immune evasion, and activate the body’s tumor immunity mechanisms for active cancer suppression. Our researchers collaborate with experts in cancer research and cell therapy to be a leader in immuno-oncology innovation. Read about our research.

CLINICAL TRIAL PARTNERS

dr-david-fletcher-large

Dr. Dean W. Felsher,
MD, PhD

Stanford University
School of Medicine

PHENYLKETONURIA (PKU)

Our researchers and collaborators are committed to finding a cure for PKU. We are developing and anticipate testing genetic medicines in humans in 2018 that may be used to treat or cure this life-threatening disease. Read about our research.

RESEARCH COLLABORATORS

Dr-Jerry-Vockley-large

Dr. Jerry Vockley, MD, PhD

University of Pittsburgh
School of Medicine

Dr-Steven-Dobrowolski-large

Dr. Steven Dobrowolski, PhD

University of Pittsburgh
School of Medicine

OTHER COLLABORATORS

Our proprietary lentiviral vectors deliver genetic medicines that have shown to both disable key drivers of tumor growth or immune evasion, and activate the body’s tumor immunity mechanisms for active cancer suppression. Our researchers collaborate with experts in cancer research and cell therapy to be a leader in immuno-oncology innovation. Read about our research.

dr-ted-dawson-large

Dr. Ted Dawson,
MD, PhD

Johns Hopkins
University

robert-clark-large

Dr. Robert Clarke,
Ph.D., D.Sc.

Georgetown University
Medical School

fred-nyberg-large

Dr. Fred Nyberg,
PhD

Uppsala University,
Sweden

BOARD OF DIRECTORS

Jeffrey A. Galvin<br/>
CEO and Founder

Jeffrey A. Galvin

CEO and Founder

Jeff earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of…

tommy-thompson-large

Tommy Thompson

Director and Senior Advisor

Tommy Thompson, former Secretary of the United States Department of Health and Human Services, worked fervently to modernize healthcare delivery as the former Governor of…

aaron-galvin-large

Aaron Galvin

Director

Aaron Galvin earned his BS and MS from the Massachusetts Institute of Technology (MIT), joining the MIT Lincoln Labs to pioneer innovations to radar as well as developing technologies for various classified…

qi-tang-large

Qi Tang

Director

Qi Tang has developed manufacturing and import/export businesses throughout China and the United States, and has invested several times throughout AGT’s growth.

Julia R. Brown<br/>
Director at AGT

Julia Brown

Director

Julia Brown has served on the board of directors of nine drug development companies with a focus on governance and compensation. She currently serves on the board and as a member of the…

PROFESSIONAL ADVISORS

snell-small

Snell & Wilmer strategically develops our intellectual property.

foley-small

Foley & Lardner protects our innovative technologies and cures.

cooley-small

Cooley, LLP provides AGT with corporate legal advice.

eyoung-small

Ernst & Young serves as our independent public accountant.